AOD-9604
AOD-9604 (5mg)
$120USD
Third-Party Tested
Independent lab verified
Batch-Specific CoA
Publicly accessible
YPB.248
Reference number
5mg
Lyophilized vial
C-terminal fragment of human growth hormone (hGH176-191). Studied for lipolytic effects without IGF-1 stimulation.
Origin
AOD-9604 is a synthetic peptide corresponding to the C-terminal fragment (amino acids 176-191) of human growth hormone. It was developed by Frank Ng and colleagues at Monash University in Melbourne, Australia, based on the observation that this region of GH was responsible for lipolytic activity independent of the growth-promoting (somatotropic) domain.
Research Lineage
Ng et al. published the initial characterization in the 1990s, demonstrating that the hGH(176-191) fragment retained fat-mobilizing activity without stimulating IGF-1 production or affecting blood glucose. Metabolic Pharmaceuticals (later Calzada Ltd.) advanced it through Phase II clinical trials for obesity. It received GRAS (Generally Recognized As Safe) status from the FDA as a food ingredient in 2007.
Mechanism of Action
AOD-9604 has been observed to stimulate lipolysis and inhibit lipogenesis in adipocyte cell culture without activating the GH receptor's JAK2/STAT5 signaling cascade that drives IGF-1 production. The mechanism is proposed to involve a distinct receptor or binding site in adipose tissue, separate from the somatogenic GH receptor. Beta-3 adrenergic receptor involvement has been investigated.
Structural Notes
16-amino-acid peptide. Corresponds to hGH residues 176-191 with a tyrosine modification. Molecular weight: ~1815 Da. C-terminal fragment — does not contain the GH receptor binding domains (Site I or Site II).
Key References
Ng FM et al. J Mol Endocrinol. 2000;25(3):287-98.
Heffernan M et al. Endocrinology. 2001;142(12):5182-9.
Research Use Only. This product is intended for laboratory research purposes only. Not for human or veterinary use. Not for sale to minors.